TY - JOUR
T1 - Clinical Translational Potentials of Stem Cell-Derived Extracellular Vesicles in Type 1 Diabetes
AU - Hu, Wei
AU - Song, Xiang
AU - Yu, Haibo
AU - Sun, Jingyu
AU - Wang, Hongjun
AU - Zhao, Yong
N1 - Publisher Copyright:
Copyright © 2022 Hu, Song, Yu, Sun, Wang and Zhao.
PY - 2022/1/12
Y1 - 2022/1/12
N2 - Type 1 diabetes (T1D) is an organ-specific disease characterized by the deficiency of insulin caused by the autoimmune destruction of pancreatic islet β cells. Stem cell-based therapies play essential roles in immunomodulation and tissue regeneration, both of which hold great promise for treating many autoimmune dysfunctions. However, their clinical translational potential has been limited by ethical issues and cell transplant rejections. Exosomes are small extracellular vesicles (EVs) released by almost all types of cells, performing a variety of cell functions through the delivery of their molecular contents such as proteins, DNAs, and RNAs. Increasing evidence suggests that stem cell-derived EVs exhibit similar functions as their parent cells, which may represent novel therapeutic agents for the treatment of autoimmune diseases including T1D. In this review, we summarize the current research progresses of stem cell-derived EVs for the treatment of T1D.
AB - Type 1 diabetes (T1D) is an organ-specific disease characterized by the deficiency of insulin caused by the autoimmune destruction of pancreatic islet β cells. Stem cell-based therapies play essential roles in immunomodulation and tissue regeneration, both of which hold great promise for treating many autoimmune dysfunctions. However, their clinical translational potential has been limited by ethical issues and cell transplant rejections. Exosomes are small extracellular vesicles (EVs) released by almost all types of cells, performing a variety of cell functions through the delivery of their molecular contents such as proteins, DNAs, and RNAs. Increasing evidence suggests that stem cell-derived EVs exhibit similar functions as their parent cells, which may represent novel therapeutic agents for the treatment of autoimmune diseases including T1D. In this review, we summarize the current research progresses of stem cell-derived EVs for the treatment of T1D.
KW - autoimmunity
KW - exosome
KW - extracellular vesicle
KW - immunomodulation
KW - stem cell
KW - type 1 diabetes
KW - β-cell regeneration
UR - http://www.scopus.com/inward/record.url?scp=85123417835&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123417835&partnerID=8YFLogxK
U2 - 10.3389/fendo.2021.682145
DO - 10.3389/fendo.2021.682145
M3 - Review article
AN - SCOPUS:85123417835
VL - 12
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
M1 - 682145
ER -